NCT03316807View on ClinicalTrials.gov

Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2018

Conditions
Hepatitis B Vaccine
Interventions
BIOLOGICAL

60 µg dose hepatitis B vaccine

three-dose, 60 µg per dose

BIOLOGICAL

20 µg dose hepatitis B vaccine

three-dose, 20 µg per dose

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention, China

OTHER_GOV

lead

Suping Wang

OTHER

NCT03316807 - Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults | Biotech Hunter | Biotech Hunter